

30 April 2001

Roy Castle, HFD-205
Food and Drug Administration
Park Lawn Building, Room 12B05
Fishers Lane, MD 20857

**Reference: NDA 20-920
Natrecor® (nesiritide)
Cardiovascular and Renal Drugs Advisory Committee Briefing Document**

Dear Mr. Castle:

Please find attached another copy of the January 11, 1999 Cardiovascular and Renal Drugs Advisory Committee Briefing Document with the Scios confidential logo removed. This briefing document, and the current document for the May 25, 2001 Advisory Committee meeting, was submitted to the Advisors and Consultants Staff on April 24, 2001 with the exception of the confidential logo.

It was Scios' intention to provide this briefing document for public disclosure. When the briefing document was printed, it was done so utilizing Scios' routine printing paper. We would like to apologize for this error and hope that this has not inconvenienced the Freedom of Information division. To help assist you, Scios is providing the briefing document as a paper copy and on CD.

Should you require further assistance, please do not hesitate to contact me at (408) 616-8591.

Sincerely,

A handwritten signature in black ink, appearing to read 'Klara A. Dickinson', with a long horizontal flourish extending to the right.

Klara A. Dickinson,
Senior Manager, Regulatory Affairs